Related references
Note: Only part of the references are listed.Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Veronique Corbiere et al.
CANCER RESEARCH (2011)
Neutropenia associated with rituximab therapy
Cliona Grant et al.
CURRENT OPINION IN HEMATOLOGY (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes
Stefano Ugel et al.
BLOOD (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
James N. Kochenderfer et al.
BLOOD (2010)
Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
John P. Diaz et al.
GYNECOLOGIC ONCOLOGY (2010)
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
Dhanalakshmi Chinnasamy et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Ying Xie et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells
Eleanor J. Cheadle et al.
JOURNAL OF IMMUNOLOGY (2010)
Genetic redirection of T cells for cancer therapy
Jennifer A. Westwood et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
A CD20 tandem-epitope immunogen elicits antibody in mice that binds murine cell surface CD20 and depletes splenic B cells in vivo
Jon Oscherwitz et al.
MOLECULAR IMMUNOLOGY (2010)
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Renier Brentjens et al.
MOLECULAR THERAPY (2010)
Of Mice, Not Men: No Evidence for Graft-versus-Host Disease in Humans Receiving T-Cell Receptor-Transduced Autologous T Cells
Steven A. Rosenberg
MOLECULAR THERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
The mutation spectrum revealed by paired genome sequences from a lung cancer patient
William Lee et al.
NATURE (2010)
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Gavin M. Bendle et al.
NATURE MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
Nitya Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Asad Bashey et al.
BLOOD (2009)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy
Liuyan Jiang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
Oliver Klein et al.
CLINICAL CANCER RESEARCH (2009)
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Steven A. Rosenberg et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
Luis H. Camacho et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Monoclonal antibodies for cancer immunotherapy
Louis M. Weiner et al.
LANCET (2009)
Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma
Steven Yeh et al.
OPHTHALMOLOGY (2009)
Bioinformatics construction of the human cell surfaceome
J. P. C. da Cunha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab-based regimens treatment?
Maria J. Garcia-Rodriguez et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Adjuvant activity of type I interferons
Michael G. Tovey et al.
BIOLOGICAL CHEMISTRY (2008)
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma - A retrospective analysis of response and survival in patients treated in the Surgery Branch at the National Cancer Institute between 1986 and 2006
Jacob A. Klapper et al.
CANCER (2008)
Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell-Mediated Targeting of Carcinoembryonic Antigen
Rinke Bos et al.
CANCER RESEARCH (2008)
Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer
Wan-Lung Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
Douglas C. Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer
Helga Bernhard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder
Makoto Hirokawa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Enhancement of human melanoma antigen expression by IFN-β
Ian S. Dunn et al.
JOURNAL OF IMMUNOLOGY (2007)
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis
Manuela Kaspar et al.
CANCER RESEARCH (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project
June M. McKoy et al.
LEUKEMIA RESEARCH (2007)
A case of hyperthyroidy developing in pegylated-interferon therapy
Mehmet Aslan et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic significance of autoimmunity during treatment of melanoma with interferon
H Gogas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies
KD Lute et al.
BLOOD (2005)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A critical function for type I interferons in cancer immunoediting
GP Dunn et al.
NATURE IMMUNOLOGY (2005)
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2
KA Chianese-Bullock et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dendritic cells as therapeutic vaccines against cancer
J Banchereau et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in Her-2/neu transgenic mice
M Lo Iacono et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2005)
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma
K Sanderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger
LEUKEMIA (2005)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Modelling paraneoplastic CNS disease:: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat
H Pellkofer et al.
BRAIN (2004)
Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
CM Bollard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Cytokines in cancer immunity and immunotherapy
MJ Smyth et al.
IMMUNOLOGICAL REVIEWS (2004)
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission -: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
CM Wendtner et al.
LEUKEMIA (2004)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma - A new cause of uveitis
MR Robinson et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Neuroimmunology of the paraneoplastic neurological degenerations
WK Roberts et al.
CURRENT OPINION IN IMMUNOLOGY (2004)
Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: Differential diagnosis and possible pathogenesis
Y Herishanu et al.
LEUKEMIA & LYMPHOMA (2003)
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
WW Overwijk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Alerntuzumab therapy in B-cell lymphoproliferative disorders
P Moreton et al.
SEMINARS IN ONCOLOGY (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-α
JL Steegmann et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma
L Ridolfi et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
CL Slingluff et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
PG Fraenkel et al.
JOURNAL OF IMMUNOTHERAPY (2002)
T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells
M Afkarian et al.
NATURE IMMUNOLOGY (2002)
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotug) therapy
P Rajvanshi et al.
BLOOD (2002)
Rituximab: Mechanism of action and resistance
DG Maloney et al.
SEMINARS IN ONCOLOGY (2002)
Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder.
F Suzan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy
A van Elsas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Guidelines for the safe administration of high-dose interleukin-2
DJ Schwartzentruber
JOURNAL OF IMMUNOTHERAPY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The CD52 antigen and development of the CAMPATH antibodies
G Hale
CYTOTHERAPY (2001)
Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
C Yee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia
NM Tannir et al.
LEUKEMIA & LYMPHOMA (2000)
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
B Ludewig et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
